NAT Screening of Blood Donations in NBC, TRCS
|
|
- Vivien Parker
- 6 years ago
- Views:
Transcription
1 IPFA/PEI, Italy
2 NAT Screening of Blood Donations in NBC, TRCS Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine service for HIV/HCV (on request) % of blood donations screened by Procleix HIV-1/HCV (IDT) June 2006: moved to Ultrio HIV-1/ HCV/ HBV (MP16) 2007 One year evaluation of NAT screening for HIV-1/HBV/HCV by Procleix Ultrio/Tigris system (IDT) vs cobas s 201/MPX v1 system (MP6) cobas s 201 system and MPX v1 (MP6) 2014 Change to MPX v2 (MP6)
3 TTIs Screening Algorithm at TRC All blood donations initially tested by Abbott Architect i6000 for: - HBsAg, Anti-HCV, HIV Ab/Ag Combo & Syphilis Confirmatory test - HBsAg reactive Abbott HBsAg Neutralization test Only serology negative (HBsAg, Anti-HCV, HIV Ab/Ag ) samples tested by NAT - Samples tested in pools of 6 with Roche cobas MPX test v1 and MPX v2 on cobas s 201 platform
4 Prevalence of Serological and NAT Markers in Thai Blood Donations tested at NBC and RBCs in 2013 Test No. tested Syphilis HBsAg Anti-HCV HIV Ag/Ab Serology 1,813,821 3,811 (0.32%) 14,225 (1.2%) 4,100 (0.35%) 1,383 (0.12%) Test No. tested NAT yield HBV HCV HIV NAT 1,404,634 1 :
5 NAT Tests: cobas MPX v1 and MPX v2 Donations tested in pools of 6 Donations in reactive pools tested individually to identify reactive donation MPX v1 Multiplex test for simultaneous detection of HBV DNA, HCV RNA, HIV-1 RNA and HIV-2 RNA Reactive donations tested with COBAS TaqMan (CAP/CTM)/ COBAS AmpliScreen tests for HBV, HCV and HIV-1 to identify viral target in reactive donation (VTR) MPX v2 Multiplex test for simultaneous detection of HBV DNA, HCV RNA, HIV-1 RNA and HIV-2 RNA and identification of HBV, HCV and HIV (viral target resolution testing not required)
6 Donor primary tubes (serology negative) Pool of 6 Flow Chart of NAT Testing of Blood Donations with the cobas TaqScreen MPX v1 NAT for HIV/HCV/HBV Initial reactive pool Test 6 samples from reactive pool using samples from primary tubes or archive plate Pool nonreactive Release all 6 donations All 6 samples non- reactive Reactive samples Repeat from plasma bags (duplicate) Non reactive One or both replicates reactive Viral Target Resolution *** with sample from bag HIV Reactive unit Discard blood unit Follow-up donor - full HBV serology profile and NAT Nonreactive unit Non- reactive unit Send to Siriraj Hospital for comfirmation (high speed centrifugation + COBAS AmpliScreen Test) Reactive unit Discard blood unit Follow up donor - full HBV serology profile and NAT HCV HBV
7 Serology and NAT Screening, MPX v1(2013) Parameters Results Serology No. of donations screened 640,137 No. of sero-positive donations 4,606 (0.72%) NAT screen No. of donations screened 595,059 No. of pools screened 99,180 No. of initially reactive pools 437 (0.44%) No. of pools that resolved to 1 or more reactive donations (repeat reactive) 248 (0.25%) No. of false reactive pools 189 (0.19%)
8 NAT-only Yield, MPX v1(2013) Parameters Results No. of reactive donations on pool resolution (RR) 248 No. of RR/ not confirmed (samples from plasma bags) donations 55 (22.2%)** No. of RR/ confirmed (samples from plasma bags) donations 193 (77.8%) No. of RR/confirmed, VTR-negative donations 35 (18.1%)** No. of RR/confirmed, VTR-positive donations 158 (81.9%) (5 HIV,2 HCV, 151 HBV) No. of RR/confirmed, HBV VTR-positive donors followed 41 out of 151 (27.2%)** ** Follow up donor full HBV serology profile & NAT
9 MPX v1: Follow-up Data from RR/Not Confirmed Donors 31 of 55 (56%) RR/ not confirmed donors were followed (follow-up samples from 1-13 months after index donation) All donors were negative for HBsAg and anti-hbc IgM ALT ranged from 7-44 IU/L, 5/30 (17%) >35 IU/L, 1 donor ALT = 226 IU/L Serology + NAT markers No. of donors HBV status All negative 1 False reactive Anti-HBc 2 Occult Anti-HBs 3 Occult Anti-HBc +anti-hbs 12 Occult Anti-HBc +anti-hbs + anti-hbe 8 Occult Anti-HBc + NAT 1 Occult Anti-HBs + NAT 1 Occult Anti-HBc +anti-hbs + NAT 1 Occult Anti-HBc +anti-hbs + anti-hbe + NAT 2 Occult
10 MPX v1: Follow-up Data from RR/Confirmed/VTR Negative Donors 21 of 35 (60%) RR/Confirmed/VTR Negative donors were followed (samples from 1-19 months after index donation) T ranged from IU/L, 1 donor ALT = 43 IU/L ALT ranged from IU/L (1 donor ALT = 43 IU/L, 1 donor = 61 IU/L ) Serology + NAT markers No. of donors HBV status NAT 1* Acute WP infection HBsAg + NAT 1* Acute WP infection Anti-HBc +anti-hbs 8 Occult Anti-HBc +anti-hbs + anti-hbe 4 Occult Anti-HBc + NAT 2 Occult Anti-HBc +anti-hbs +NAT 3 Occult Anti-HBc +anti-hbs + anti-hbe + NAT 2 Occult * 1 month follow-up sample
11 MPX v1: Follow-up Data from HBV Reactive Donors 41 of 151 HBV-reactive donors (27.2%) were followed NAT + full HBV serology profile were done on follow-up samples 12 breakthrough infections 2 unclassified 3 acute infections 24 occult HBV infections
12 MPX v1: HBV NAT and Serology Profile of Donor Follow-up Samples - Breakthrough HBV Infection? Donor no. Followup (months) ALT HBsAg Anti-HBs (miu/ml) Anti- HBc IgM Anti-HBc IgG Anti-HBe > NAT (Ct) > > > > > >
13 MPX v1: HBV NAT and Serology Profile of Donor Followup Samples - Unclassified? Donor no. Followup (months) ALT HBsAg Anti-HBs (miu/ml) Anti-HBc IgM Anti-HBc IgG Anti-HBe NAT (Ct)
14 MPX v1: HBV NAT and Serology Profile of Donor Followup Samples - Acute HBV Infection? Donor no. Followup (months) ALT HBsAg Anti-HBs (miu/ml) Anti-HBc IgM Anti-HBc IgG Anti-HBe NAT (Ct)
15 HBV NAT and Serology Profile of Donor Follow-up: Occult HBV Infection? Possible occult HBV infection: 24donors Follow-up sample from 1-13 months after index donation A ALT ranged from 8-72 IU/L, 6/25 (24%) >35 IU/L from 8-72 IU/L, 6/25 (24%) >35 Serology + NAT markers No. of donors HBV status Anti-HBc + anti-hbs 8 Occult Anti-HBc + anti-hbe 1 Occult Anti-HBc + anti-hbs + anti-hbe 5 Occult Anti-HBc + anti-hbs + NAT 2 Occult Anti-HBc + anti-hbe + NAT 5 Occult Anti-HBc +anti-hbs + anti-hbe + NAT 3 Occult
16 Donor primary tubes (serology negative) Pool of 6 Flow Chart of NAT Testing of Blood Donations with the cobas TaqScreen MPX v2 NAT for HIV/HCV/HBV Initial Reactive pool Test 6 samples from reactive pool using samples from archive plate Pool nonreactive Release all 6 donations All 6 samples non- reactive Reactive samples HIV/HBV/HCV Repeat from plasma bags (duplicate) Non reactive One or both replicate reactive Discard blood unit NAT on 5 replicates Follow-up donor by NAT NAT testing 5-10 replicates Discard blood unit Follow up donor - full HBV serology profile and NAT
17 MPX v2: NAT-only Yield Parameters Results No. of donations screened 189,087 No. of pools screened 31,517 No. of initially reactive pools 135 (0.42%) No. of pools that resolved to one or more reactive donations 48 (0.15%) No. of false reactive pools 87(0.28%) No. of RR/ confirmed (samples from plasma bags) donations 44 (91.7%) 2 HIV, 42 HBV No. of RR/ not confirmed (samples from plasma bags) donations 4 (8.3%)* *Since MPX v2 was a new test, all RR/not confirmed samples were retested (5-10 replicates)
18 MPX v2: HBV NAT and Serology Profile of 4 Repeat Reactive/Not Confirmed Donors Donor no. Replicate testing No. reactive/no. tested Sex Age Anti-HBs (>10 IU/L positive) Anti-HBc IgM Anti-HBc Anti-HBe ALT /5 M 26 + (26.29) /10 M 59 - (5/16) /10 F 30 - (<2.0) /10 F 51 + (75.46)
19 Conclusions Both MPXv1 & MPXv2 gave the same percentage of initially reactive pools (0.44% %). MPX v1: Almost all follow up donors of RR/not confirmed and RR/ confirmed/vtr negative donations were occult HBV, although 2 of the later group were acute infections. Majority of confirmed HBV reactive donors also had occult HBV. Occult MPX v2: Majority of RR/not confirmed HBV donations had occult HBV with very low viral load. Study shows that majority of HBV infections in Thai blood donors tested by NAT had occult HBV. Some of them can be extremely difficult to detect. Testing of NAT RR sample with multiple replicate as well as full HBV serology profile are important to confirm HBV low viral load.
20 Question
21 Prevalence of serological markers(%) in blood donations tested at NBC and RBCs in % 1.40% 1.20% 1.00% 0.80% 0.60% 0.40% 0.20% 0.00% Syphilis HBsAg Anti-HCV HIV Ag/Ab NBC 0.12% 0.34% 0.15% 0.01% Central R(RBC2,3,4) 0.36% 0.98% 0.14% 0.11% Northeast R(RBC 5,6,7) 0.35% 1.35% 0.59% 0.14% North R (RBC 8,9,10) 0.31% 1.51% 0.35% 0.10% South R (RBC 11,12, Phuket) 0.29% 0.78% 0.21% 0.13%
22 NAT yield rate tested at NBC & RBC in 2013 NAT center No. of samples tested Number of reactive samples (NAT yield) HIV HCV HBV No plasma sample to be confirmed/vtr NBC, TRCS 636,330 (NAT Yield) 5 (1:127,000) 2 (1:318,000) 163 (1:3,900) 0 Central & East R (RBC 2,3,4) 252,077 (NAT Yield) 4 (1:63,000) 3 (1:84,000) 90 (1:2,800) 47 Northeast R (RBC 5,6,7) 192,706 (NAT Yield) 3 (1:64,000) 1 (1: 192,000) 82 (1:2,400) 97 North R (RBC 8,9,10) 190,484 (NAT Yield) 2 (1:95,000) 1 (1:190,000) 113 (1:1,700) 51 South R (RBC11,12, Phuket) 133,037 (NAT Yield) 2 (1: 67,000) 0 38 (1: 3,500) 17 Overall NAT Yield 1,404, (1:88,000) 7 (1: 200,000) 486 (1: 2,900) 212
Impact of multi-dye multiplex technology on testing algorithm
Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT
More information2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1
More informationConfirmatory Testing Algorithm. Routine Donor Testing Algorithm
Confirmatory Testing Algorithm Blood Confirmatory ABO/Rh Beckman Coulter PK-ABO/Rh Immucor NEO ABO/Rh Immucor NEO ABO/Rh Immucor Manual ABO/Rh Typing Immucor Manual ABO/Rh Typing Discrepancy Resolution
More informationDonor Screening in The Region. Vincini GA NRL, Melbourne, Australia
Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management
More informationHEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS. Joana Bikulčienė Director of National blood center
HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS Joana Bikulčienė Director of National blood center j.bikulciene@kraujodonoryste.lt Organizational structure of Lithuanian blood service 1 specialized
More informationImpact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company
More informationRoutine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors
Journal of the Egyptian Society of Haematology & Research, Vol. 7, No. 2, September: 1-5, 2011 Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors HISHAM
More informationProbability of false initial and repeat ID-NAT reactive donations. Marion Vermeulen IPFA Rome 2014
Probability of false initial and repeat ID-NAT reactive donations Marion Vermeulen IPFA Rome 2014 Overview of SANBS SANBS is a non profit organization Provides a vein to vein blood transfusion service
More informationNational Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands. TransMed conference Bhopal 18 November 2016
Dr. Anton van Weert National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands TransMed conference Bhopal 18 Introduction Thank you! Anton van Weert, PhD, MBA Manager
More informationKhalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia
1 Regional Lab, Makkah. Saudi Arabia stract: Clinical specificity and genotype/subtype detection of viruses using the Cobas TaqScreen MPX system V 2.0, which is a nucleic acid test (NAT) that uses multiples
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationUpdate from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012
Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012 SOGAT XXIV Ljubljana, 8-9 May 2013 2012 ISS EQAs for NAT ISS EQA Tri-NAT (HCV,
More informationFrequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion
More informationErgebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI
Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI NAT for cellular blood components in Germany Definition of minimal NAT sensitivity limit (ID)
More informationrisk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)
Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)
More informationHEPATITIS B AND HEPATITIS C VIRUS AMONG BLOOD DONORS
HEPATITIS B AND HEPATITIS C VIRUS AMONG BLOOD DONORS VIRAL HEPATITIS PREVENTION BOARD MEETING LISBON, PORTUGAL, 18 19 November 2010 Gabriel de Olim Presidente do Conselho Directivo do Instituto Português
More informationThe Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing
PERMISSON TO USE: Please note that, by making their presentations available on-line, primary authors have agreed to share their presentations. However, should you want to use some of the data or slides
More informationAccuVert HBV Seroconversion Panel PHM941(M) ( )
PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics
More informationTitle: Reactivation of a Hepatitis B without core antibody: a case report.
JCM Accepted Manuscript Posted Online 28 January 2015 J. Clin. Microbiol. doi:10.1128/jcm.03546-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 1 Title: Reactivation of a Hepatitis
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationBLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine
BLOOD SAFETY STATUS IN INDONESIA Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine OUTLINE Background Blood services in Indonesia Regulation related to blood safety in Indonesia
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationUvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication
UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication Citation for published version (APA): Lieshout-Krikke, R. W. (2016). Residual
More informationAccuSet HBV Worldwide Performance Panel
PACKAGE INSERT 0805-033 INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HBV test methods. Characterized samples
More informationEvaluation of external NAT controls from two manufacturers
Evaluation of external NAT controls from two manufacturers Aneta Kopacz, Institute of Hematology and Transfusion Medicine, Warsaw, Poland NAT and External QC in Poland (2018) SCREENING Regional Blood Transfusion
More informationThe testing of Donated Blood and Components at NHSBT
The testing of Donated Blood and Components at NHSBT NHSBT is responsible for collecting all donated blood and platelets in England, then processing into components before issuing to client hospitals.
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationLearning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016
New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationFDA Reentry Guidance
FDA Reentry Guidance T. cruzi - Chagas, Hepatitis C and HIV Wednesday 6/6/18 Doug Denyer O Dina Hurlburt, SBB(ASCP)CM Outline Impact to Clients Review of FDA Guidance Documents Reentry Request Process
More informationNon-competitive Internal Control Concept for PCR-based Qualitative Assays
Christian O. Simon Roche Molecular Diagnostics Rotkreuz, CH Non-competitive Internal Control Concept for PCR-based Qualitative Assays 23 rd SoGAT Meeting, 16 th 17 th April, 2012, Vilnius, Lithuania Design
More informationNAT / BLOOD SCREENING - PRODUCT RANGE
NAT / BLOOD SCREENING - PRODUCT RANGE QC Sample Name Analytes Assay / Instrument Page QConnect TriScreen Roche cobas TaqScreen MPX Test, v 2.0 (s201) Roche cobas MPX Test (6800/8800) QConnect Grifols Ultrio
More informationINTERPRETING HEPATITIS B SEROLOGY
INTERPRETING HEPATITIS B SEROLOGY RECOMMENDED WORDING FOR NATIONAL LABORATORIES TO REPORT HEPATITIS B DIAGNOSTIC TEST RESULTS THIS DOCUMENT HAS BEEN ENDORSED BY: Australasian Society for HIV Medicine,
More informationScreening donors and donations for transfusion transmissible infectious agents. Alan Kitchen
Screening donors and donations for transfusion transmissible infectious agents Alan Kitchen Aim Not to teach you microbiology To provide and awareness of the big picture To provide an understanding of
More informationEvolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention
Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like
More informationChallenges in HBV detec1on in blood donors
Challenges in HBV detec1on in blood donors Jean- Pierre Allain Dept Haematology, University of Cambridge, UK Phylogene1c analysis of human and ape HBV over 1me of evolu1on (Pareskevis et al, Hepatology
More informationSince 1973 all blood donations in the Netherlands
ORIGINAL RESEARCH Rare transmission of hepatitis B virus by Dutch donors with occult infection Ryanne W. Lieshout-Krikke, 1 Marian G.J. van Kraaij, 2 Fikreta Danovic, 2 and Hans L. Zaaijer 1 BACKGROUND:
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationIsolated Hepatitis B Core Antibody
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Isolated Hepatitis B Core Antibody Nina Kim, MD MSc Associate Professor of Medicine November 13, 2014 Isolated Core Antibody Virology & terminology Definition
More informationComplicated viral infections
Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western
More informationIn October 2005, the South African National Blood
DONOR INFECTIOUS DISEASE TESTING Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk_3355
More informationHEV Assay Development Update
HEV Assay Development Update Jeffrey M. Linnen, Ph.D. Senior Director, Research & Development Hologic Gen-Probe, San Diego, California USA IPFA/PEI 20th International Workshop on Surveillance and Screening
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationBlood Screening Assays. CTS lab locations where assays are performed are indicated by alpha codes D, P, and T.
Blood Screening Assays CTS lab locations where assays are performed are indicated by alpha codes D, P, and T. D= performed in Dallas lab FEI: 3002580251 P= performed in Phoenix lab FEI: 3000204058 T= performed
More informationStructure and duties of Blood service
NATIONAL CENTER FOR TRANSFUSION MEDICINE Prevalence of infectious diseases among Mongolian blood donors Namjil Erdenebayar General director of The National Center for Transfusion Medicine, Mongolia NCTM,
More informationAnnual SHOT Report 2016 Supplementary Information. Chapter 17: Transfusion-Transmitted Infections (TTI)
Annual SHOT Report 2016 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.3 which can be viewed in the main report. Case reports
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationProposed 1 st IS for Hepatitis E Virus RNA WHO/BS/
www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:
More informationEvaluation of run controls for cobas 6800 MPX and HEV assay
Evaluation of run controls for cobas 6800 MPX and HEV assay Marco Koppelman Head of Nucleic Acid testing (NAT) laboratory, National Screening laboratory of Sanquin (NSS) in the Netherlands Satellite Meeting
More informationHIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings
HIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings Elizabeth M. Dax with the staff of the National Serology Reference Laboratory, Australia My Background Worked in HIV
More informationQuality Control Solutions
Quality Control Solutions 1 CONTENT QCONNECT 3 ABOUT DIAMEX 6 ABOUT NRL 7 ABOUT EXACT DIAGNOSTICS 7 PRODUCTS 8 SEROLOGY MULTIMARKER RANGE 10 SEROLOGY SINGLE ANALYTE RANGE 16 NAT CONTROL RANGE 19 EXACT
More informationDEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE
DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE SoGAT Clinical Diagnostics III 12-13 January 2011, London Michael Chudy Julia Kreß Micha Nübling Paul-Ehrlich-Institut
More informationChapter 17: Transfusion-Transmitted Infections (TTI)
Annual SHOT Report 2014 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.2 which can be viewed in the main report. Case reports
More informationExternal Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience
External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience Giulio Pisani Biologicals Unit CRIVIB, ISS, Rome SOGAT XXII 14 th 15 th April 2011 - Istituto Superiore di
More informationHBV PUBLIC HEALTH IMPLICATIONS
جزايری دکتر سيد محمد آزمايشگاه ھپاتيت B -دانشکده بھداشت ويروس شناسی- گروه دانشگاه علوم پزشکی تھران کنگره ارتقا کيفيت- ١٣٩٢ HBV PUBLIC HEALTH IMPLICATIONS 2 billion people have been infected by HBV worldwide.
More informationNegative Hepatitis C Reporting and Linkage to Care Outreach
Negative Hepatitis C Reporting and Linkage to Care Outreach NASTAD 7 th National Hepatitis Technical Assistance Meeting November 28-30, 2017 Angelica Bocour, MPH Director of Viral Hepatitis Surveillance
More informationLab Underwriting Puzzler. Presented by: Bill Rooney, M.D.
Lab Underwriting Puzzler Presented by: Bill Rooney, M.D. Obtaining Best Results from this presentation For best results please do the following: Select Slide Show from the menu option on top Select From
More informationImpact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening
Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening IPFA Lisbon 216 Marion Vermeulen Disclaimer Race classifications are described as
More informationHepa%%s E Virus Is it a Concern?
IPFA/PEI 17 th Workshop on Surveillance and Screening of Blood Borne Pathogens 26-27 May 2010, The Regent Esplanade Zagreb Hotel, Zagreb, Croa%a Hepa%%s E Virus Is it a Concern? Keiji Matsubayashi Hokkaido
More informationINTEGRATING HIV AND HCV TESTING
INTEGRATING AND HCV TESTING OVERVIEW Increasingly health departments (HDs) are seeking new strategies to improve the productivity and yield of testing and linkage programs, expand availability of and access
More informationLookback studies to assess viral risks The French experience
Lookback studies to assess viral risks The French experience 2000-2012 S Laperche 1, MF Leconte des Floris 2, J Pillonel 3, L Hauser 2, C Lefort 2, JY Py 2, I Hervé 2, R Djoudi 2 For the French haemovigilance
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2002D0364 EN 01.07.2012 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B COMMISSION DECISION of 7 May 2002 on common technical
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091608 Age 26 Years Gender Female 30/8/2017 92900AM 30/8/2017 94717AM 31/8/2017 90216AM Ref By Final HEATITIS ACUTE VIRUS CONFIRMATION HEATITIS A ANTIBODY (ANTI HAV),
More informationOverview of the testing strategy stages that the Japanese Red Cross has gone through (HBV, HIV)
2014/LSIF/PD/006 Overview of the Testing Strategy Stages That the Japanese Red Cross (JRC) Has Gone Through (HBV, HIV) - The JRC Approach to Donor Recruitment in the Era of Aging Population Submitted by:
More informationOfficial Journal of the European Communities COMMISSION
16.5.2002 EN Official Journal of the European Communities L 131/17 COMMISSION COMMISSION DECISION of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under
More informationThe Food and Drug Administration (FDA) has
NAT Comparative analysis of triplex nucleic acid test assays in United States blood donors Susan L. Stramer, David E. Krysztof, Jaye P. Brodsky, Tracy A. Fickett, Benjamin Reynolds, Roger Y. Dodd, and
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationCALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD
CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD AAJ van Drimmelen, E.R. Bax and W.G.V. Quint, BioQControl (BQC), Delft Diagnostic Laboratories
More informationPublic Health, Infections and Transplantation
Public Health, Infections and Transplantation Dr Kerry Chant Chief Health Officer & Deputy Director General Population and Public Health NSW Ministry of Health May2014 Public Health Infection and Transplantation
More informationThe ABC s (and D & E s) of the Viral Hepatitides Part 2 DIAGNOSTIC TESTS 3/7/2013
The ABC s (and D & E s) of the Viral Hepatitides Part 2 Thomas Novicki PhD DABMM Clinical Microbiologist Division of Laboratory Medicine novicki.thomas@marshfieldclinic.org Objectives 2 1. Explain the
More informationEC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK
National Institute for Biological Standards and Control (NIBSC) EC Certificate - Full Quality Assurance System Approval Certificate Annex IV (excluding sections 4 and 6) of Council Directive 98/79/EC on
More informationWithin 14 days at 2-8⁰C. DO NOT FREEZE WHOLE BLOOD Micro Typing Systems 50 µl plasma
Test Name *Minimum Collection Tubes Sample Stability ABO/Rh Blood Typing 50 µl cells EDTA whole blood (lavender-top) Within 14 days at 2-8⁰C. DO NOT FREEZE WHOLE BLOOD Micro Typing Systems 50 µl plasma
More informationMaximizing Cornea and Tissue Donation through Specimen Quality
Maximizing Cornea and Tissue Donation through Specimen Quality Robert W. Bresler, Sydney D. Gastreich, Elias G. Koulouriotis, Linda S. Martin, Susan Diane Brockmeier, Chak-Sum Ho, PhD Abstract Purpose:
More informationClinical Application of New Treponemal Antibody Test in Blood Donors
Clinical Application of New Treponemal Antibody Test in Blood Donors Parichart Permpikul, MD Department of Transfusion Medicine Faculty of Medicine Siriraj Hospital Mahidol University Bangkok, Thailand
More informationMulticenter efficacy study of HBV, HCV and HIV blood screening scenarios
Multicenter efficacy study of HBV, HCV and HIV blood screening scenarios Steven Kleinman, Nico Lelie, Roberta Bruhn, Brian Custer, Michael Busch and the international ID-NAT user group Blood Systems Research
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationSupplementary Online Content
Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population.
More informationSEROLOGICAL STATUS OF HEPATITIS B VIRUS INFECTION AMONG MONKS AND NOVICES AT BUDDHIST MONASTERIES IN THREE TOWNSHIPS, YANGON
SEROLOGICAL STATUS OF HEPATITIS B VIRUS INFECTION AMONG MONKS AND NOVICES AT BUDDHIST MONASTERIES IN THREE TOWNSHIPS, YANGON Moe Pwint 1, Aye Marlar Win 1, Wah Win Htike 1, Khine Khine Su 2, Wai Wai Min
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationSerology for Biochemists
Serology for Biochemists Dr Ronda Greaves Diagram from: http://www.cdc.gov/hepatitis/resources/professionals/training/serology/training.htm Overview Part A: GENERAL SEROLOGY IgG vs IgM Definitions The
More informationseroprevalence of infectious markers & their trends in blood donors in a hospital based blood bank in north india
Indian J Med Res 142, September 2015, pp 317-322 DOI:1103/0971-5916.166598 seroprevalence of infectious markers & their trends in blood donors in a hospital based blood bank in north india R.N. Makroo,
More informationNon-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More stringent - recommended Not legy binding and not recommended Tested pathogen Donor test/ technique
More information(DNA) Real-time PCR. Exicycler 96 Rotor-Gene Q/6000 PCR
Real-Time (DNA) Real-time Exicycler 96 Rotor-Gene Q/6000 IU Mix1 Mix2 IU/μl IU/μl IU/μl IU/μl IU/μl IPC NTC C 1 Lot# 2 Freeze & thawing 1 MSDS: Material Safety Data Sheets (TaqMan Real-time ' FAM ' BHQ1
More informationCustomer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands
PRODUCT CATALOGUE Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 sales@bioqcontrol.com
More informationTransfusion transmitted infections in National Haemovigilance Systems: the Greek experience
Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience Global blood product safety 10 April 2019, Rome, Italy Constantina Politis National Coordinating Haemovigilance
More informationHIV Testing Technology and the Latest Algorithm
HIV Testing Technology and the Latest Algorithm David Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene HIV Testing has changed over time Patients with
More informationThe cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets
More informationCustomer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands
PRODUCT CATALOGUE Customer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 info@bioqcontrol.com www.bioqcontrol.com
More informationGuidance for Industry
Guidance for Industry Advisement for the Use of Gen-Probe Procleix Ultrio Plus Assay for NAT Testing on Cadaveric Donors Release Date: 08/03/14 American Medical Education and Research Association 4757
More informationHepatitis Serology and Background Notes
Hepatitis Serology and Background Notes Updated and presented by David Dickeson 2012 Collated by Evelyn Crewe 2010 Centre for Infectious Diseases & Microbiology Laboratory Services Institute of Clinical
More informationHepatitis B. Hepatitis Viruses. Hepatitis Viruses. Hepatitis Viruses
Hepatitis Viruses Hepatitis B History and Overview of Hepatitis B Testing in Australia Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Cytomegalovirus Epstein-Barr Virus Hepatitis Viruses Hepatitis
More informationLaboratory Diagnosis of Viral Infections. G. Jamjoom 2005
Laboratory Diagnosis of Viral Infections G. Jamjoom 2005 Five Main Techniques: Virus Culture and Isolation Serology Rapid Detection of Viral Antigens Detection of Viral Nucleic Acid Electron Microscopy
More informationStability of native, lyophilized and inactivated standards
Stability of native, lyophilized and inactivated standards Harry van Drimmelen Bio Quality Control, Heiloo, Netherlands Satellite Meeting before IPFA-PEI 25 th Workshop Twenty-five Years Standardization
More informationHUNGARIAN NATIONAL BLOOD TRANSFUSION SERVICE. Dr. Klara Baroti-Tóth, PhD IPFA/PEI 19 th International Workshop Budapest, May, 2012.
HUNGARIAN NATIONAL BLOOD TRANSFUSION SERVICE Dr. Klara Baroti-Tóth, PhD IPFA/PEI 19 th International Workshop Budapest, 23-24 May, 212. BLOOD DONATION G I V I N G I S G O O D ORGAN COORDINATION OFFICE
More informationAdventures in Discordance- HIV Testing
Anne Gaynor, PhD On behalf of Monica M. Parker, PhD Director, Bloodborne Viruses Laboratory Wadsworth Center, NYSDOH Adventures in Discordance- HIV Testing HIV Laboratory Testing Algorithm HIV-1/2 antigen/antibody
More informationAssays to Address Emerging Threats to Blood Safety
Assays to Address Emerging Threats to Blood Safety Jeffrey M. Linnen, Ph.D. Director, Product Development Gen-Probe Incorporated San Diego, CA The IPFA/PEI 17th Workshop on Surveillance and Screening of
More informationGuide to the preparation, use and quality assurance of blood components
Contents Foreword...3 Members of the European Committee (Partial Agreement) on Blood Transfusion... 8 Members of the GTS working group... 22 Members of the TS066 working group... 30 Recommendation No.
More informationNew HIV Tests and Algorithm: A change we can believe in
New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be
More information